Cingulate (CING) Total Liabilities (2021 - 2026)
Cingulate's (CING) quarterly Total Liabilities came in at $12.6 million in Q4 2025, up 69.58% YoY from $7.4 million in Q4 2024, and up 78.34% on a QoQ basis from $7.0 million in Q3 2025.
Cingulate (CING) Total Liabilities (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Total Liabilities data on file, last reported at $12.6 million in Q4 2025.
- Quarterly Total Liabilities rose 69.58% year-over-year to $12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.6 million (up 69.58% YoY) and the FY2025 annual result came in at $12.6 million, up 69.58% from the prior year.
- Total Liabilities rose to $12.6 million in Q4 2025, from $7.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $12.6 million in Q4 2025 to a low of $1.5 million in Q3 2024.
- A 5-year average of $5.9 million and a median of $6.8 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities jumped 599.57% — and 2024, when it slumped 81.96%.
- Tracing CING's Total Liabilities over 5 years: stood at $2.0 million in 2021, then jumped by 268.29% to $7.5 million in 2022, then soared by 37.72% to $10.4 million in 2023, then dropped by 28.49% to $7.4 million in 2024, then surged by 69.58% to $12.6 million in 2025.
- The last three Total Liabilities figures came in at $12.6 million (Q4 2025), $7.0 million (Q3 2025), and $6.5 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 9.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.60 Mn |
| Dec 31, 2025 | 12.56 Mn |
| Sep 30, 2025 | 7.05 Mn |
| Mar 31, 2025 | 6.54 Mn |
| Dec 31, 2024 | 7.41 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | 10.36 Mn |
| Sep 30, 2023 | 5.97 Mn |
| Jun 30, 2023 | 11.33 Mn |
| Mar 31, 2023 | 7.08 Mn |
| Dec 31, 2022 | 7.52 Mn |
| Sep 30, 2022 | 7.01 Mn |
| Jun 30, 2022 | 1.62 Mn |
| Mar 31, 2022 | 2.41 Mn |
| Dec 31, 2021 | 2.04 Mn |